Journal of Biological Chemistry · 2008 · 129 citations · 26 references
Life SciencesBiochemistryImmunologyCell SignalingProtein BiochemistrySignal TransductionPlatelet ActivationPlatelet PhysiologyProteolytic ProcessingFibrinolytic RegulationHemostasis ModulationReceptor Proteolytic Cleavage
Chemerin is a potent chemoattractant for cells expressing the serpentine receptor CMKLR1 (chemokine-like receptor 1), such as plasmacytoid dendritic cells and tissue macrophages. The bioactivity of chemerin is post-translationally regulated; the attractant circulates in blood in a relatively inactive form (prochemerin) and is activated by carboxyl-terminal proteolytic cleavage. We discovered that plasma carboxypeptidase N (CPN) and B (CPB or activated thrombin-activable fibrinolysis inhibitor, TAFIa) enhanced the bioactivity of 10-mer chemerin peptide NH2-YFPGQFAFSK-COOH by removing the carboxyl-terminal lysine (K). Sequential cleavages of either a prochemerin peptide (NH2-YFPGQFAFSKALPRS-COOH) or recombinant full-length prochemerin by plasmin and CPN/CPB substantially increased their chemotactic activities. Endogenous CPN present in circulating plasma enhanced the activity of plasmin-cleaved prochemerin. In addition, we discovered that platelets store chemerin protein and release it upon stimulation. Thus circulating CPN/CPB and platelets may potentially contribute to regulating the bioactivity of leukocyte chemoattractant chemerin, and further extend the molecular link between blood coagulation/fibrinolysis and CMKLR1-mediated immune responses. Chemerin is a potent chemoattractant for cells expressing the serpentine receptor CMKLR1 (chemokine-like receptor 1), such as plasmacytoid dendritic cells and tissue macrophages. The bioactivity of chemerin is post-translationally regulated; the attractant circulates in blood in a relatively inactive form (prochemerin) and is activated by carboxyl-terminal proteolytic cleavage. We discovered that plasma carboxypeptidase N (CPN) and B (CPB or activated thrombin-activable fibrinolysis inhibitor, TAFIa) enhanced the bioactivity of 10-mer chemerin peptide NH2-YFPGQFAFSK-COOH by removing the carboxyl-terminal lysine (K). Sequential cleavages of either a prochemerin peptide (NH2-YFPGQFAFSKALPRS-COOH) or recombinant full-length prochemerin by plasmin and CPN/CPB substantially increased their chemotactic activities. Endogenous CPN present in circulating plasma enhanced the activity of plasmin-cleaved prochemerin. In addition, we discovered that platelets store chemerin protein and release it upon stimulation. Thus circulating CPN/CPB and platelets may potentially contribute to regulating the bioactivity of leukocyte chemoattractant chemerin, and further extend the molecular link between blood coagulation/fibrinolysis and CMKLR1-mediated immune responses. Chemerin is a recently discovered chemoattractant molecule that is predicted to share structural similarity with cystatins (cysteine protease inhibitors) and cathelicidin precursors (antibacterial peptides) (1Zabel B.A. Zuniga L. Ohyama T. Allen S.J. Cichy J. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1106-1114Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar). Chemerin is present in circulating blood and several human inflammatory fluids (1Zabel B.A. Zuniga L. Ohyama T. Allen S.J. Cichy J. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1106-1114Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar). Even though chemerin is not similar to CXC and CC chemokines based on primary amino acid sequence, it functions like a chemokine in that it induces leukocyte migration and intracellular calcium mobilization. Chemerin receptor chemokine-like receptor 1 (CMKLR1, 3The abbreviations used are: CMKLR1, chemokine-like receptor 1; CPN, carboxypeptidase N; CPB, carboxypeptidase B; TAFI, thrombin-activable fibrinolysis inhibitor; MGTA, dl-2-mercaptomethyl-3 guanidinoethylthiopropanoic acid; PPACK, d-phenylalanyl-l-prolyl-l-arginine chloromethyl ketone; HPLC, high performance liquid chromatography; PRP, platelet-rich plasma; PIPES, piperazine-N,N′-bis(2-ethanesulfonic acid); RT, reverse transcription; ELISA, enzyme-linked immunosorbent assay; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; PPP, platelet-poor plasma. also named ChemR23) is a G protein-coupled receptor specifically expressed by circulating human plasmacytoid dendritic cells, natural killer cells, and tissue macrophages (1Zabel B.A. Zuniga L. Ohyama T. Allen S.J. Cichy J. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1106-1114Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar, 2Zabel B.A. Silverio A.M. Butcher E.C. J. Immunol. 2005; 174: 244-251Crossref PubMed Scopus (221) Google Scholar, 3Wittamer V. Franssen J.D. Vulcano M. Mirjolet J.F. Le Poul E. Migeotte I. Brézillon S. Tyldesley R. Blanpain C. Detheux M. Mantovani A. Sozzani S. Vassart G. Parmentier M. Communi D. J. Exp. Med. 2003; 198: 977-985Crossref PubMed Scopus (729) Google Scholar, 4Zabel B.A. Ohyama T. Zuniga L. Kim J.Y. Johnston B. Allen S.J. Guido D.G. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1021-1032Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar, 5Parolini S. Santoro A. Marcenaro E. Luini W. Massardi L. Facchetti F. Communi D. Parmentier M. Majorana A. Sironi M. Tabellini G. Moretta A. Sozzani S. Blood. 2007; 109: 3625-3632Crossref PubMed Scopus (322) Google Scholar). In their capacity as antigen-presenting cells, plasmacytoid dendritic cells and macrophages can influence the activation of many other cell types, including monocytes, myeloid dendritic cells, B cells, T cells, and natural killer cells; thus chemerin appears to be an important chemoattractant in both innate and adaptive immune responses (2Zabel B.A. Silverio A.M. Butcher E.C. J. Immunol. 2005; 174: 244-251Crossref PubMed Scopus (221) Google Scholar, 6Zhang Z. Wang F.S. Cell Mol. Immunol. 2005; 2: 411-417PubMed Google Scholar, 7Wittamer V. Bondue B. Guillabert A. Vassart G. Parmentier M. Communi D. J. Immunol. 2005; 175: 487-493Crossref PubMed Scopus (208) Google Scholar). Chemerin circulates in blood in an inactive prochemerin form at low nanomolar concentrations (∼3 nm) (4Zabel B.A. Ohyama T. Zuniga L. Kim J.Y. Johnston B. Allen S.J. Guido D.G. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1021-1032Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). Its chemotactic activity is released following proteolytic cleavage of its carboxyl-terminal amino acids by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades (4Zabel B.A. Ohyama T. Zuniga L. Kim J.Y. Johnston B. Allen S.J. Guido D.G. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1021-1032Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar, 8Zabel B.A. Allen S.J. Kulig P. Allen J.A. Cichy J. Handel T.M. Butcher E.C. J. Biol. Chem. 2005; 280: 34661-34666Abstract Full Text Full Text PDF PubMed Scopus (311) Google Scholar). These include factor XIIa, VIIa, plasmin, neutrophil elastase, and mast cell tryptase. Of interest, staphopain B, a cysteine protease secreted by Staphylococcus aureus, also cleaves prochemerin and converts it into a potent chemoattractant (9Kulig P. Zabel B.A. Dubin G. Allen S.J. Ohyama T. Potempa J. Handel T.M. Butcher E.C. Cichy J. J. Immunol. 2007; 178: 3713-3720Crossref PubMed Scopus (56) Google Scholar). Interestingly, the cleavage sites in the labile carboxyl terminus (NH2-YFPGQFAFSKALPRS-COOH) are not conserved, and the cleavage products generated by chemerin-activating proteases display different potencies in bioactivity assays. Based on synthetic peptides, the 9-mer NH2-YFPGQFAFS-COOH is the most active, but it is still not as active as intact cleaved chemerin protein, indicating that the amino-terminal part of chemerin is required for maximal activity (4Zabel B.A. Ohyama T. Zuniga L. Kim J.Y. Johnston B. Allen S.J. Guido D.G. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1021-1032Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar, 10Wittamer V. Grégoire F. Robberecht P. Vassart G. Communi D. Parmentier M. J. Biol. Chem. 2004; 279: 9956-9962Abstract Full Text Full Text PDF PubMed Scopus (154) Google Scholar). Plasma carboxypeptidases CPN and CPB cleave the basic amino acids arginine or lysine from the carboxyl terminus of proteins or peptides such as bradykinin and complement proteins C3a and C5a. CPN is a constitutively active zinc metalloprotease present in plasma at a concentration of about 100 nm and is considered the major anaphylatoxins inhibitor (11Matthews K.W. Mueller-Ortiz S.L. Wetsel R.A. Mol. Immunol. 2004; 40: 785-793Crossref PubMed Scopus (134) Google Scholar), generating inactive “desArg” forms of C3a and C5a. In contrast, CPB exists in plasma as a proenzyme, proCPB, or thrombin-activable fibrinolysis inhibitor (TAFI) at a concentration of about 50 nm and is activated by thrombin in complex with thrombomodulin on the vascular endothelial surface. CPB inhibits fibrin degradation by removing carboxyl-terminal lysines from partially digested fibrin, which prevents further incorporation of fibrinolytic plasminogen and tissue plasminogen activator (12Redlitz A. Tan A.K. Eaton D.L. Plow E.F. J. Clin. Investig. 1995; 96: 2534-2538Crossref PubMed Scopus (242) Google Scholar, 13Bajzar L. Morser J. Nesheim M. J. Biol. Chem. 1996; 271: 16603-16608Abstract Full Text Full Text PDF PubMed Scopus (610) Google Scholar). CPB is thermolabile and has a half-life of ∼15 min at 37 °C (14Ceresa E. Van de Borne K. Peeters M. Lijnen H.R. Declerck P.J. Gils A. J. Biol. Chem. 2006; 281: 15878-15883Abstract Full Text Full Text PDF PubMed Scopus (30) Google Scholar). We have shown that CPB also has broad substrate reactivity and is able to cleave and inactivate bradykinin, C3a, C5a, and thrombin-cleaved osteopontin (15Myles T. Nishimura T. Yun T.H. Leung L.L.K. J. Biol. Chem. 2003; 278: 51059-51067Abstract Full Text Full Text PDF PubMed Scopus (196) Google Scholar, 16Nishimura T. Myles T. Piliponsky A.M. Kao P.N. Berry G.J. Leung L.L.K. Blood. 2007; 109: 1992-1997Crossref PubMed Scopus (51) Google Scholar, 17Myles T. Leung L.L. J. Biol. Chem. 2008; 283: 17789-17796Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar). CPN and CPB may play complementary roles, with the former being constitutively active and capable of regulating systemic anaphylatoxins, and the latter activated locally at sites of vascular injury to provide site-specific anti-inflammatory control. Peptidases can also modulate the biological activity of certain chemokines (4Zabel B.A. Ohyama T. Zuniga L. Kim J.Y. Johnston B. Allen S.J. Guido D.G. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1021-1032Abstract Full Text Full Text PDF PubMed Scopus (118) Google Scholar). For example, dipeptidyl peptidase (DPP-IV/CD26), a serine protease, inactivates CXCL9, CXCL10, CXCL11, and CXCL12 by cleaving these chemokines in the amino terminus (18Hildebrandt M. Schabath R. Front. Biosci. 2008; 13: 1774-1779Crossref PubMed Scopus (12) Google Scholar, 19Gonzalez-Gronow M. Kaczowka S. Gawdi G. Pizzo S.V. Front. Biosci. 2008; 13: 1610-1618Crossref PubMed Scopus (42) Google Scholar). Platelets store a variety of potent cytokines and chemokines within α-granules that are released upon cell activation. Platelet degranulation products, particularly the leukocyte chemoattractants, which include CXCL4 (platelet factor 4), β-thromboglobulin, CCL5 (RANTES), CCL7 (monocyte chemotactic protein 3), and CXCL12 (stromal-derived factor 1), may contribute to host defense and also play a role in pathophysiologic conditions (20Boehlen F. Clemetson K.J. Transfus. Med. 2001; 11: 403-417Crossref PubMed Scopus (143) Google Scholar, 21Brandt E. Ludwig A. Petersen F. Flad H.D. Immunol. Rev. 2000; 177: 204-216Crossref PubMed Scopus (148) Google Scholar). For example, platelet factor 4 forms complexes with heparin in blood or some glycosaminoglycans on platelet surfaces to form the major antigen implicated in heparin-induced thrombocytopenia (22Warkentin T.E. Chong B.H. Greinacher A. Thromb. Haemostasis. 1998; 79: 1-7Crossref PubMed Scopus (562) Google Scholar, 23Cines D.B. Rauova L. Arpelly G. Reilly M.P. McKenzie S.E. Sachais B.S. Poncz M. J. Clin. Apher. 2007; 22: 31-36Crossref PubMed Scopus (60) Google Scholar). Platelets not only store CXCL12 but also express its receptor CXCR4, a coreceptor for cellular entry of human immunodeficiency virus, type 1, suggesting that platelets may be involved in host defense (24Clemetson K.J. Clemetson J.M. Proudfoot A.E. Power C.A. Baggiolini M. Wells T.N. Blood. 2000; 96: 4046-4054Crossref PubMed Google Scholar). In this study, we found that plasma CPN or CPB can function in concert with plasmin to elicit and augment the chemotactic activity of prochemerin. Furthermore, we show that platelets could store and release partially active chemerin upon activation. Thus circulating CPN/CPB and platelets may contribute to regulating the bioactivity of leukocyte chemoattractant chemerin and further extend the molecular link between blood coagulation/fibrinolysis and CMKLR1-mediated immune responses. Materials—Recombinant human chemerin21–157, polyclonal goat anti-human chemerin antibodies, and biotinylated polyclonal goat anti-human antibodies were from R & D Systems (Minneapolis, MN). Peptides 9-mer, YFPGQFAFS (chemerin149–157); 10-mer, YFPGQFAFSK (chemerin149–158); and 15-mer, YFPGQFAFSKALPRS (chemerin149–163) were synthesized by Elim Biopharmaceuticals (Hayward, CA). Human plasmin and α-thrombin were purchased from Hematologic Technologies (Essex Junction, VT). dl-2-Mercaptomethyl-3 guanidinoethylthiopropanoic acid (MGTA) was obtained from Calbiochem (La Jolla, CA). Collagen and ADP were from Chrono-log (Havertown, PA). Human plasma-derived CPB (TAFIa) and a CPB activity kit were from American Diagnostica (Stamford, CT). Thrombin peptide d-phenylalanyl-l-prolyl-l-arginine chloromethyl and were from Human thrombomodulin and recombinant CPN were from and CA). and cells were from the American of prochemerin was as B.A. Allen S.J. Kulig P. Allen J.A. Cichy J. Handel T.M. Butcher E.C. J. Biol. Chem. 2005; 280: 34661-34666Abstract Full Text Full Text PDF PubMed Scopus (311) Google Scholar). prochemerin with a carboxyl-terminal was into and into The prochemerin protein has the amino acid the are not prochemerin was expressed by high to cells in for at the was by to and at 4 °C a with a was by and reverse The protein was and for cells were with human CMKLR1 or and in with and 1 In with were used for the assays. of cells in were to the and were to the in of The cells that to the at 37 °C were by and the are as in the of and Platelet was into and platelet-rich plasma following Clemetson J.M. A. Wells T.N. Clemetson K.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). plasma was by the at for min at The platelets were with PIPES, 4 and at as Clemetson J.M. A. Wells T.N. Clemetson K.J. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). Platelet were obtained by platelets with with protease The was at and the protein concentration was by protein was from human platelets and and cells by was to the and The used for a chemerin were and was of Chemerin Peptides the of synthetic chemerin 10-mer cleavage by CPN or CPB, 50 of 10-mer was with either CPN or CPB nm) for min at 37 and the were a and with a in acid by For was with plasmin at for the was by protease CPN or CPB nm) was and for min at 37 of plasmin, plasmin and was by reverse as of of 10-mer Chemerin Peptides by CPB and was used to the and for the of 10-mer peptide by CPB and The concentrations of 10-mer peptides from to and were digested with 50 nm CPB or nm CPN for min at 37 °C in The were by for peptide was by HPLC, and the of peptide generated was from the of cleaved The for and were by the of cleavage the different substrate concentrations and to the by as (15Myles T. Nishimura T. Yun T.H. Leung L.L.K. J. Biol. Chem. 2003; 278: 51059-51067Abstract Full Text Full Text PDF PubMed Scopus (196) Google Scholar). The were in and the were for CPB of CPN nm) and CPB nm) were to a in the or of at the 50 of CPB (TAFIa) substrate was used in as in the CPB CPB (TAFIa) from to was used to the of the were in The was in an at 37 °C with and the at nm was min of for goat anti-human chemerin antibodies were used to at a concentration of 4 polyclonal goat anti-human chemerin antibodies and was used to chemerin The of of chemerin in this was For the of chemerin in the were was by the and are expressed as the and was were considered to be or CPN and CPB Chemerin 10-mer by the synthetic 9-mer chemerin peptide YFPGQFAFS migration of human with a at not to the 9-mer not The 10-mer peptide YFPGQFAFSK not at concentration of the 10-mer peptide with CPN or CPB, substantially enhanced the chemotactic activity of the peptide CPN and CPB at 100 nm) not migration We the of 10-mer with either CPN or CPB by and found that the a major with a of which is to that of the 9-mer and different from the 10-mer For the 10-mer with CPB, we major to the 10-mer and 9-mer The of 10-mer cleavage by CPB at nm was about CPB is thermolabile the conditions In this CPN was also used at nm to with CPB Of the plasma of and CPN are and 100 (11Matthews K.W. Mueller-Ortiz S.L. Wetsel R.A. Mol. Immunol. 2004; 40: 785-793Crossref PubMed Scopus (134) Google Scholar, E. Van de Borne K. Peeters M. Lijnen H.R. Declerck P.J. Gils A. J. Biol. Chem. 2006; 281: 15878-15883Abstract Full Text Full Text PDF PubMed Scopus (30) Google Scholar). of the for the of 10-mer by CPB and of by CPB for and The concentrations of from to and chemerin was digested with 50 nm The for chemerin cleavage was about with bradykinin and but with the of 10-mer cleavage by CPN is which is about CPB, and is about bradykinin and peptide but similar to that of C3a of chemerin 10-mer peptides by CPB and in a Sequential of by and synthetic chemerin YFPGQFAFSKALPRS (chemerin149–163) is of the with CPN or CPB on chemerin of the with plasmin and CPN or CPB enhanced its chemotactic The proteolytic products were by to cleaved the to 10-mer the with the at min is the carboxyl-terminal CPN or CPB the 10-mer to the 9-mer Sequential of by and of concentrations of prochemerin by plasmin and CPN or CPB could the attractant and the NH2-YFPGQFAFS-COOH cleaved prochemerin and increased its chemotactic bioactivity Sequential of prochemerin with plasmin and CPN or CPB, enhanced its chemotactic activity The proteolytic products were by to the sites cleaved prochemerin to the NH2-YFPGQFAFSK-COOH form and CPN or CPB the lysine to a form with enhanced with CPN and CPB not CMKLR1-mediated not Endogenous Plasma CPN for the of was with plasmin and with to serine protease prochemerin was to platelet-poor plasma as as with MGTA, a inhibitor for CPN but not CPB prochemerin not CMKLR1-mediated with PPP, increased its which was by MGTA, indicating that plasma CPN is for low concentrations of plasmin-cleaved chemerin of Chemerin in store proteins as as inflammatory platelets are also involved in chemerin and were Chemerin was by in platelet with a molecular of similar to recombinant platelets are are present in the including for certain chemokines C.A. Clemetson J.M. Clemetson K.J. Wells T.N. 1995; PubMed Scopus Google Scholar). We chemerin in platelets by was from of as as from cell and cell cells of the chemerin was by Platelets Chemerin upon by ELISA, the concentration of chemerin in was The of thrombin to increased the chemerin to The of thrombin to PPP, on the other on chemerin Thrombin not the of cells, and thrombin not cleave and B.A. Allen S.J. Kulig P. Allen J.A. Cichy J. Handel T.M. Butcher E.C. J. Biol. Chem. 2005; 280: 34661-34666Abstract Full Text Full Text PDF PubMed Scopus (311) Google Scholar). Thus we that the increased chemerin bioactivity in was not to of circulating plasma prochemerin by thrombin but was on the release of chemerin from platelets following thrombin activation. Furthermore, such as thrombin to a ADP the release of chemerin from platelets which with an in chemerin bioactivity as by CMKLR1 migration We the chemerin released from activated platelets is a prochemerin form or an active The of prochemerin and active were used as for chemerin by in Chemerin activity released from activated platelets is prochemerin but substantially active The of chemerin to CMKLR1 was in the cells as that platelets release chemerin in a partially active or chemerin is a of different forms of chemerin, which could further to express its biological activities. the of or to platelet enhanced chemerin were which is to the of plasmin including which is to be released from activated platelets E.F. D. Blood. PubMed Google not were partially by as B.A. Allen S.J. Kulig P. Allen J.A. Cichy J. Handel T.M. Butcher E.C. J. Biol. Chem. 2005; 280: 34661-34666Abstract Full Text Full Text PDF PubMed Scopus (311) Google Scholar), a increased chemerin activity was plasmin, and Interestingly, chemerin activity was also enhanced in the of CPN or CPB indicating that at a of the released from activated platelets has cleaved to a form that is to CPN or CPB cleavage. In this study, we that plasma-derived CPN and CPB substantially the bioactivity of plasmin-cleaved prochemerin the of the carboxyl-terminal lysine a to prochemerin and activation by proteases We this in different in CPN and CPB the carboxyl-terminal lysine from a 10-mer chemerin peptide and it to a plasmin cleaved prochemerin to 10-mer, which was to the 9-mer by CPN or and of recombinant prochemerin protein by plasmin by CPN or CPB generated a chemerin with potent chemoattractant activity These show that CPN and CPB a active form of plasmin-cleaved Interestingly, we also found that platelets can chemerin bioactivity by and it upon stimulation. We have circulating that contribute to the of chemerin bioactivity and further link the of blood coagulation/fibrinolysis with that leukocyte cleavages by acid in a is a for the role of and serine proteases such as and G in regulating the activity of chemokines at the (1Zabel B.A. Zuniga L. Ohyama T. Allen S.J. Cichy J. Handel T.M. Butcher E.C. Exp. Hematol. 2006; 34: 1106-1114Abstract Full Text Full Text PDF PubMed Scopus (123) Google Scholar). These are particularly at chemokines to immune responses. For example, CCL7 is a substrate of CCL7 as a chemokine by to but not the and leukocyte and C.A. I. 2000; PubMed Scopus Google Scholar). CPN and CPB are for their to inactivate a of including C5a, C3a, bradykinin, and thrombin-cleaved osteopontin (15Myles T. Nishimura T. Yun T.H. Leung L.L.K. J. Biol. Chem. 2003; 278: 51059-51067Abstract Full Text Full Text PDF PubMed Scopus (196) Google Scholar, 16Nishimura T. Myles T. Piliponsky A.M. Kao P.N. Berry G.J. Leung L.L.K. Blood. 2007; 109: 1992-1997Crossref PubMed Scopus (51) Google Scholar, 17Myles T. Leung L.L. J. Biol. Chem. 2008; 283: 17789-17796Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar). In the of plasmin-cleaved CPN/CPB the chemotactic activity of the attractant the that are include plasmacytoid dendritic cells and capable of as in the of plasmacytoid dendritic cell and macrophages may play an immune and factor and regulating T cell responses. Thus CPN/CPB may to inflammatory responses by anaphylatoxins and by immune to sites of tissue The of chemerin bioactivity at a of tissue injury in appears to a complex many In study, plasmin at 1 cleaves prochemerin in this is a concentration of plasmin, human platelets have plasminogen and these sites are further increased by upon platelet activation Plow E.F. J. Biol. Chem. Full Text PDF PubMed Google Scholar, Plow E.F. J. Clin. Investig. PubMed Scopus Google Scholar). In addition, it has that thrombin specifically induces plasminogen activation that is by plasminogen activator C. V. Blood. PubMed Google Scholar). Thus the plasma concentration of plasminogen it is that upon release from activated be cleaved to chemerin by plasmin generated locally at the of vascular in prochemerin can be further activated by CPB and CPB is activated locally by endothelial cell and the chemotactic activity of plasmin-cleaved prochemerin of the carboxyl-terminal the CPB, in its role as a fibrinolysis inhibitor, plasmin which the activation of circulating prochemerin. Thus CPB may the of prochemerin activation but the activity of the plasmin-cleaved chemerin that has further that CPB functions not only as an inhibitor of but also as a of inflammatory responses. CPB may be important for and at sites of tissue constitutively active CPN may its Platelets are in Thromb. 2004; Full Text Full Text PDF PubMed Scopus Google Scholar, K.J. Clemetson J.M. 2007; 13: PubMed Scopus (25) Google Scholar). platelets release proteins that include platelet and at the of vascular which may play a role in tissue and Mol. 2006; PubMed Scopus Google Scholar, P. Petersen F. E. Thromb. Haemostasis. 2007; PubMed Scopus Google Scholar, K. M. Thromb. Haemostasis. 2007; PubMed Scopus Google Scholar). In study, we found that platelets store platelets release a of chemerin with different of of further to express its biological the role of chemerin in platelet and tissue
26
Inflammation Dampened by Gelatinase A Cleavage of Monocyte Chemoattractant Protein-3
G. Angus McQuibban, Jiang-Hong Gong, Eric M. Tam et al. · Science · 2000 · 773 citations